A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) (PALBONET)
A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
Sponsor: Grupo Espanol de Tumores Neuroendocrinos
A PHASE2 clinical study on Pancreatic Neuroendocrine Cancer, this trial is completed. The trial is conducted by Grupo Espanol de Tumores Neuroendocrinos and has accumulated 8 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2018 — Feb 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grupo Espanol de Tumores Neuroendocrinos
For direct contact, visit the study record on ClinicalTrials.gov .